Titan Pharma up as FDA clears opioid use disorder therapy study

Titan Pharmaceuticals

05/07/2022 16:38

** Shares in specialty pharmaceutical co Titan
Pharmaceuticals Inc  TTNP.O  rise 4.3% to $0.55
    ** U.S. FDA clears co's application to start early-stage
trial of nalmefene implant, which is intended for prevention of
relapse following opioid detoxification in adults with opioid
use disorder  urn:newsml:reuters.com:*:nPn8s2dvJa
    ** In December, co said it was exploring strategic
alternatives to enhance shareholder value, including an
acquisition, merger, reverse merger, other business combinations
 urn:newsml:reuters.com:*:nL1N2T610S
    ** Stock down ~46% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))